EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer

• DOI: 10.1016/j.celrep.2022.111827
• Publication Date: 2022-12-13T16:25:19Z
• Authors: JiHoon Kang; Jaemoo Chun; Jung Seok Hwang; Chaoyun Pan; Jie Li; Austin C. Boese; Isabelle Young; Courteney M. Malin; Yibin Kang; Don L. Gibbons; Gabriel Sica; Haian Fu; Suresh S. Ramalingam; Lingtao Jin; Sumin Kang
• Keywords: ErbB Receptors; 0301 basic medicine; 0303 health sciences; 03 medical and health sciences; Lung Neoplasms; Cell Line, Tumor; Humans; Phosphorylation; Cyclic AMP Response Element-Binding Protein; Ribosomal Protein S6 Kinases, 90-kDa; Article; 3. Good health

The cancer metastasis process involves dysregulated oncogenic kinase signaling, but how this orchestrates metabolic networks and signal cascades to promote metastasis is largely unclear. Here we report that inhibition of glutamate dehydrogenase 1 (GDH1) and ribosomal S6 kinase 2 (RSK2) synergistically attenuates cell invasion, anoikis resistance, and immune escape in lung cancer and more evidently in tumors harboring epidermal growth factor receptor (EGFR)-activating or EGFR inhibitor-resistant mutations. Mechanistically, GDH1 is activated by EGFR through phosphorylation at tyrosine 135 and, together with RSK2, enhances the cAMP response element-binding protein (CREB) activity via CaMKIV signaling, thereby promoting metastasis. Co-targeting RSK2 and GDH1 leads to enhanced intratumoral CD8 T cell infiltration. Moreover, GDH1, RSK2, and CREB phosphorylation positively correlate with EGFR mutation and activation in lung cancer patient tumors. Our findings reveal a crosstalk between kinase, metabolic, and transcription machinery in metastasis and offer an alternative combinatorial therapeutic strategy to target metastatic cancers with activated EGFRs that are often EGFR therapy resistant.